[Irbesartan].
Caballero
E
E
Servicio de Farmacología Clínica, Facultad de Medicina, Universidad de Navarra.
Sádaba
B
B
Azanza
J R
JR
Honorato
J
J
D000804:Angiotensin II / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006261:Headache / Q000139:chemically induced; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D000077405:Irbesartan; D019808:Losartan / Q000494:pharmacology; D013777:Tetrazoles / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan; D019808:Losartan
Irbesartán.